Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC and JS001 in Adjuvant HER2+ UTUC
NCT05917158Phase 2Recruiting
- Sponsor
- Jinling Hospital
- Start
- Nov 2022
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, toripalimab in upper tract urothelial carcinoma (UTUC), sponsored by Jinling Hospital. Started Nov 2022; status: recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT05917158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05917158.